Follow
Less is more for monoclonal antibody affinity?
(Particularly if deletion is not the goal)
"This approach delivered higher immune cell activation, in vivo T cell expansion and antitumour activity in the case of CD40. Moreover, an inert anti-4-1BB monoclonal antibody was transformed into an agonist. Low-affinity variants of the clinically important antagonistic anti-PD-1 monoclonal antibody nivolumab also mediated more potent signalling and affected T cell activation."
#Monoclonal #MonoclonalAntibody #immunology #drugdiscovery #drugdevelopment
